Abstract: An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention.

Abstract: Methods of inducing bradycardia (slowing a heart rate) in a subject in need thereof, treating a medical condition in which inducing bradycardia (slowing a heart rate) is desirable or beneficial in a subject in need thereof and/or treating a medical condition associated with cardiac arrhythmia, are provided. The methods are effected by blocking SK4 channel in SAN cell of the subject and/or by administering to the subject a therapeutically effective amount of a blocker of an SK4 channel. A method of identifying candidate compounds for treating an arrhythmic cardiac disorder, by identifying compounds that reduce a pacing rate of the SAN cells is also provided.

Abstract: Indirect chromoendoscopy is performed by providing a subject with an orally administered composition which includes indigo carmine dye mixed with polyethylene glycol (PEG). Preferably, the subject ingests at least 160 mg of indigo carmine prior to the endoscopic procedure. This is accomplished by ingesting 1 ml to 6 L of a premixed or reconstituted indigo carmine and PEG composition up to twenty four hours prior to the endoscopic procedure.

Abstract: A device and method are provided for storing a prefilled liquid beverage, receiving an oral contrast imaging agent that is mixed with the prefilled liquid beverage, and dispensing a resulting beverage/oral contrast imaging agent mixture. The device has a body defining a chamber for storing the prefilled liquid beverage. A closure is movable between a closed position for sealing the prefilled liquid in the chamber, and an open position for (i) introducing the oral contrast imaging agent into the chamber for mixture with the prefilled liquid beverage, and (ii) dispensing the beverage/oral contrast imaging agent mixture. The device may include first graduations, a time scale and second graduations. The body defines a substantially smooth, axially extending patient information surface including thereon a plurality of marking spaces and respective patient information indicia associated with each marking space for marking thereon information relating to a respective patient.

Abstract: A cold-gelated mono-nuclear microencapsulate comprises a unitary liquid core encapsulated within a gastro-resistant, ileal-sensitive, polymerized denatured protein membrane shell, wherein the liquid core comprises a GLP-1 release stimulating agent in a substantially solubilised form. The GLP-1 release stimulating agent is a native protein selected from native dairy protein, native vegetable protein or native egg protein.

Abstract: A method of selecting a surfactant system suitable for infants and young children is disclosed.

Abstract: Disclosed herein are fiducial markers that include a sealed casing member containing a mixture of iodine and water that includes about 1-300 mg/ml iodine. The fiducial markers may be distinguishable on at least two imaging modalities, such as CT and MRI. The casing member may include a plastic or elastomeric material, such as polyvinyl chloride (PVC) polypropylene, latex, nylon, dynaflex, and may take the form of a length of IV tubing sealed at each of two ends. The length of IV tubing may be crimped to form a desired shape, such as a triangle. Also disclosed are methods of making fiducial markers that are distinguishable on at least two imaging modalities, such as CT and MRI.

Abstract: The present invention provides a soybean based non-toxic, non-hazardous, user and environmentally friendly odor trapping composition matter as a toilet spray. This product not only limits the undesired smell from defecation and releases a desirable smell, but also has potential antimicrobial properties to sanitize the toilet bowl.

Abstract: The present invention provides a novel liquid composition in the form of an emulsion or microemulsion for rectal administration comprising at least one dye, at least one emulsifier, and at least one physiologically acceptable excipient, and its use in a diagnostic endoscopic procedure of sigmoid colon and/or rectum. Preferably, said diagnostic endoscopic procedure of sigmoid colon and/or rectum is an anoscopy, a proctoscopy, a rectoscopy and/or a sigmoidoscopy.

Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.

Abstract: Provided, inter alia, are methods for treating an epilepsy disorder using a 5HT receptor agonist, or a pharmaceutically acceptable salt thereof.

Abstract: A cured non-polymeric gel including a plurality of non-polymeric cross-links. The non-polymeric cross-links result from curing an oil or oil composition at selected curing conditions to achieve a desired amount of cross-linking to form the non-polymeric gel. The desired amount of cross-linking is selected based on a desired rate of degradation of the gel after the gel is implanted. The oil or oil composition comprises one or more of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), or alpha-linolenic acid (ALA).

Abstract: A method of treating cancer in a patient comprising administering to the patient an a systemic chemotherapeutic drug regime in combination with radioactively doped particle, characterised in that the two therapies when introduced into the patient have an improved anticancer effect.

Abstract: The disclosure provides for means for a method to facilitate food intake and food retention in a mammal by applying a sufficient dose of a local anesthetic drug in the lumen of the pharyngeal-esophageal-gastric-duodenal tract before or during or after eating. The local anesthetic can be amethocaine, articaine, benzocaine, bupivacaine, chloroprocaine, cinchocaine, cyclomethycaine, dibucaine, diethocaine, etidocaine, larocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, novocaine, piperocaine, prilocaine, procaine, proparacaine, propoxycaine, QX-222, QX-314, ropivacaine, tetracaine, trimecaine, menthol, eugenol or a safe pharmaceutical formulations of tetrodotoxin, saxitoxin, or neosaxitoxin. The disclosure is useful for patients having problems with food intake or food retention.

Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: Methods and compositions for treating bedwetting are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.

Abstract: A bone graft composition comprising a viable, osteogenic cellular material combined with a viscous cryoprotectant that includes a penetrating cryoprotective agent and a non-penetrating cryoprotective agent. The viscosity of the cryoprotectant is such that the composition is malleable, cohesive and capable of being formed into desired shapes.

Abstract: A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side.

Abstract: Cosmetic compositions are provided that include an extract from a seed of the Nicotiana species, one or more cosmetically acceptable carriers to act as a diluent, dispersant or carrier for the composition, and optionally one or more cosmetic adjuvants. The tobacco seed extract is typically characterized as having a significant lipid content and, thus, finds use as an oil component in a cosmetic composition.